Screening and Characterization of a Novel RNA Aptamer That Specifically Binds to Human Prostatic Acid Phosphatase and Human Prostate Cancer Cells

Kong, Hoon Young; Byun, Jun Soo

doi:10.14348/molcells.2015.2272

Cited by 16 publications

(12 citation statements)

References 52 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (PCa), an epitheliogenic malignant tumor in prostate, is the second most common malignancy and one of the major causes for global cancer-related deaths among men, seeing about 29,000 cases in 2013 all over the world [1][2][3][4][5]. The cancer shows no obvious symptoms at early stage, which increases the risk of death among the patients [6,7]. PCa is one of the most common cancers in Occident, especially in America, its incidence rate in Asian countries is relatively low.…”

Section: Introductionmentioning

confidence: 99%

HOXC6 in the prognosis of prostate cancer

Zhou

Yang

Song

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Aims: Our study aimed to investigate the expression and prognostic role of homeobox C6 (HOXC6) in prostate cancer (PCa). Methods: Relative expression of HOXC6 at mRNA and protein levels in tissues and cell lines of PCa were measured using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis, respectively. Association between HOXC6 expression and clinical factors was analyzed by Chisquare test. HOXC6 effects on the proliferation, invasion and metastasis of PCa cells were severally examined through CCK-8 and transwell assays. Results: Relative expressions of HOXC6 at mRNA and protein levels were obviously higher in both PCa tissues and cells than in adjacent non-cancerous tissues and normal human prostate epithelial cells (p < .05). Chi-square test demonstrated that high expression of HOXC6 was significantly associated with PSA concentration, Gleason score and TNM stage (p < .05). The down-regulation of HOCX6 remarkably inhibited the proliferation, migration and invasion of PCa cells. Kaplan-Meier analysis showed that patients with high HOXC6 expression had shorter overall survival than those with low HOXC6 expression (log rank test, p < .001). Conclusion: Up-regulated HOXC6, in PCa patients, could not only participate in the progression of PCa but also function as an independent prognostic marker for the cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

HOXC6 in the prognosis of prostate cancer

Zhou

Yang

Song

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Similar results were obtained with aptamer in human prostate cancer. Elevation in prostatic acid phosphatase (PAP) is associated with prostate cancer [24]. Kong and Byun reported that 6N 2’-FY RNA aptamer with 50 nucleotide sequence contains two hairpins that facilitate binding with PAP.…”

Section: Novel Strategies For Cancer Targeted Deliverymentioning

confidence: 99%

“…Kong and Byun reported that 6N 2’-FY RNA aptamer with 50 nucleotide sequence contains two hairpins that facilitate binding with PAP. Moreover, 6N 2’-FY RNA aptamer demonstrated higher binding (118 nM) for positive PAP mammalian cells (LNCaP and PC-3) relative to normal human lung fibroblast (IMR-90) [24]. These results indicate potential application of 6N 2’-FY RNA aptamer as a targeting ligand.…”

Section: Novel Strategies For Cancer Targeted Deliverymentioning

confidence: 99%

Novel delivery approaches for cancer therapeutics

Mitra

Agrahari

Mandal

et al. 2015

Journal of Controlled Release

130

View full text Add to dashboard Cite

Currently, a majority of cancer treatment strategies are based on the removal of tumor mass mainly by surgery. Chemical and physical treatments such as chemo- and radiotherapies have also made a major contribution in inhibiting rapid growth of malignant cells. Furthermore, these approaches are often combined to enhance therapeutic indices. It is widely known that surgery, chemo- and radiotherapy also inhibit normal cells growth. In addition, these treatment modalities are associated with severe side effects and high toxicity which in turn lead to low quality of life. This review encompasses novel strategies for more effective chemotherapeutic delivery aiming to generate better prognosis. Currently, cancer treatment is a highly dynamic field and significant advances are being made in the development of novel cancer treatment strategies. In contrast to conventional cancer therapeutics, novel approaches such as ligand or receptor based targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, have added new modalities for cancer treatment. These approaches have led to selective detection of malignant cells leading to their eradication with minimal side effects. Lowering, multi-drug resistance and involving influx transportation in targeted drug delivery to cancer cells can also contribute significantly in the therapeutic interventions in cancer.

show abstract

“…In addition, the incidence rate of PCa in Asian regions has signi cantly increased in recent years though advanced therapies including surgery, hormone therapy, chemotherapy and radiation therapy had been applied in PCa patients [3,4]. Besides, it has been reported that PCa is one of the leading causes for cancer-related deaths in men [5,6]. According to the guidelines of European Association of Urology and American Urological Association, the current diagnosis of PCa mainly depends on digital rectal examination (DRE) and increased prostate speci c antigen (PSA), which have several limitations, such as low diagnostic speci city and missed diagnosis [7,8].…”

Section: Introductionmentioning

confidence: 99%

“…According to the guidelines of European Association of Urology and American Urological Association, the current diagnosis of PCa mainly depends on digital rectal examination (DRE) and increased prostate speci c antigen (PSA), which have several limitations, such as low diagnostic speci city and missed diagnosis [7,8]. What's more, the development of PCa was a slow process and majority of PCa patients are present with no obvious symptoms at early stage [5,9]. Therefore, it is in urgent need to nd novel biomarkers with high sensitivity and speci city to diagnosed PCa at early stage.…”

Section: Introductionmentioning

confidence: 99%

MiR-378 Has the Capacity to Serve as a Diagnostic Biomarker for Prostate Cancer Patient

Cao

Zheng

2020

Preprint

View full text Add to dashboard Cite

Background: This study aimed to examine the expression of serum miR-378 in prostate cancer (PCa) patients and healthy individuals and to identify the value of miR-378 in PCa diagnosis.Methods: The expression of serum miR-378 between groups was compared by t-test. The association between miR-378 expression and clinical characteristics of PCa patients was assessed using Chi-square test. The diagnostic value of serum miR-378 in PCa was estimated by the receiver operating characteristic (ROC) analysis.Results: The expression level of serum miR-378 in PCa patients was significantly lower than that in healthy individuals (P<0.0001). MiR-378 expression was affected by positive AR (P=0.004), large Gleason score (P=0.013) and advanced TNM stage (P=0.020), however, it had no relationship with age, serum PSA, NED rate and urine retention (all, P>0.05). The ROC curve showed that the optimal cutoff value was 1.845, giving the sensitivity and specificity of 75.21% and 89.77%, respectively. Besides, the area under the ROC curve (AUC) was 0.894, indicating serum miR-378 was of great diagnostic value in screening PCa patients from healthy controls (P<0.0001, 95%CI =0.852-0.936).Conclusions: Taken together, the increased expression of serum miR-378 might act as a potential biomarker for PCa diagnosis.

show abstract

Screening and Characterization of a Novel RNA Aptamer That Specifically Binds to Human Prostatic Acid Phosphatase and Human Prostate Cancer Cells

Cited by 16 publications

References 52 publications

HOXC6 in the prognosis of prostate cancer

HOXC6 in the prognosis of prostate cancer

Novel delivery approaches for cancer therapeutics

MiR-378 Has the Capacity to Serve as a Diagnostic Biomarker for Prostate Cancer Patient

Contact Info

Product

Resources

About